This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioMarin To Advance BMN-701 For Pompe Disease To Next Phase Of Development

Table: BMN-701 Phase 1/2 Results as Compared to LOTS Study*

    POM-001       LOTS  
    BMN-701       Alglucosidase Alfa  
  Baseline Change from baseline  % Chg   Baseline Change from baseline % Chg
    at Week 24       at Week 26  
 Avg. 6MWT (meters) 354.5 22.3 6.3%   332.2 28.5 8.6%
 Super Responders n= 16 3 18.8%   n=60 4 6.7%
    POM-001       LOTS
    BMN-701       Alglucosidase Alfa
  Baseline Week 24 Change % Chg    Baseline Week 26 Change % Chg 
       % predicted from baseline        % predicted from baseline
 FVC 58.1% 59.3% 1.2% 2.0%   55.4% 56.9% 1.5% 2.7%
 MVV (L/min) 67.6 70.6 2.9 4.3   na na na na
 MEP 36.4% 41.6% 5.1% 14.1%   32.0% 34.6% 2.6% 8.0%
 MIP 40.6% 51.6% 11.0% 27.0%   40.0% 45.0% 5.0% 12.5%

*The LOTS trial (N Engl J Med 2010;362:1396-406) was a randomized, placebo-controlled trial of alglucosidase alfa, recombinant human GAA, for the treatment of late-onset Pompe's disease. Ninety patients who were eight years of age or older, ambulatory, and free of invasive ventilation were randomly assigned to receive biweekly intravenous alglucosidase alfa (20 mg/kg) or placebo. The two primary endpoints were 6-minute walk distance and percentage of predicted forced vital capacity (FVC). Comparison to LOTS study data roughly estimated at week 26 are presented to provide additional information regarding BioMarin's decision making process for the continued development of BMN-701. As the trials were independently conducted and utilized different protocols, no inference should be made about the comparative efficacy of the products tested.

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.21 -1.00%
FB $118.09 0.56%
GOOG $696.13 0.54%
TSLA $222.39 -4.30%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,653.49 -97.42 -0.55%
S&P 500 2,051.82 -11.55 -0.56%
NASDAQ 4,728.7270 -34.4970 -0.72%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs